Are Pain Polymorphisms Associated with the Risk and Phenotype of Post-COVID Pain in Previously Hospitalized COVID-19 Survivors?

Szczegóły
Abstrakt

Tytuł:: Are Pain Polymorphisms Associated with the Risk and Phenotype of Post-COVID Pain in Previously Hospitalized COVID-19 Survivors?
Autorzy:: Fernández-de-Las-Peñas C; Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorcón, Spain.; Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.
Giordano R; Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.
Díaz-Gil G; Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.
Gil-Crujera A; Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.
Gómez-Sánchez SM; Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.
Ambite-Quesada S; Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorcón, Spain.
Arendt-Nielsen L; Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.; Department of Medical Gastroenterology, Mech-Sense, Aalborg University Hospital, DK-9000 Aalborg, Denmark.
Źródło:: Genes [Genes (Basel)] 2022 Jul 26; Vol. 13 (8). Date of Electronic Publication: 2022 Jul 26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Basel : MDPI
MeSH Terms:: COVID-19*/complications
COVID-19*/genetics
Neuralgia*/genetics
Neuralgia*/virology
Adult ; Aged ; Female ; Hospitalization ; Humans ; Male ; Middle Aged ; Phenotype ; Polymorphism, Single Nucleotide ; Survivors ; Post-Acute COVID-19 Syndrome
References:: Pharmacol Rev. 1999 Dec;51(4):593-628. (PMID: 10581325)
Psychiatry Res. 1989 May;28(2):193-213. (PMID: 2748771)
Lancet. 2007 Oct 20;370(9596):1453-7. (PMID: 18064739)
Med Clin (Barc). 2008 Oct 18;131(13):487-92. (PMID: 19007576)
Aging Dis. 2018 Jun 1;9(3):523-536. (PMID: 29896439)
Rheumatol Int. 2012 Feb;32(2):417-26. (PMID: 21120487)
Hum Mol Genet. 2005 Jan 1;14(1):135-43. (PMID: 15537663)
Pain. 2017 Jul;158(7):1194-1203. (PMID: 28282362)
Infection. 2022 Feb;50(1):285-286. (PMID: 34519974)
Sci Rep. 2016 Mar 24;6:23639. (PMID: 27010666)
BMC Musculoskelet Disord. 2006 May 04;7:40. (PMID: 16674809)
Int Rev Neurobiol. 2010;95:227-79. (PMID: 21095465)
PLoS One. 2010 Oct 26;5(10):e13641. (PMID: 21049025)
J Pain Res. 2021 Aug 10;14:2403-2412. (PMID: 34408485)
J Pain. 2009 Sep;10(9):895-926. (PMID: 19712899)
Clin J Pain. 2019 Jan;35(1):77-86. (PMID: 30028366)
BMC Genet. 2020 Jul 20;21(1):79. (PMID: 32689951)
Cephalalgia. 2017 May;37(6):592-598. (PMID: 27154995)
Front Psychiatry. 2021 Jul 12;12:696655. (PMID: 34322042)
Pain Pract. 2012 Apr;12(4):276-85. (PMID: 21951710)
Ann Rheum Dis. 2010 Nov;69(11):2009-12. (PMID: 20570835)
J Pain. 2005 Mar;6(3):159-67. (PMID: 15772909)
Science. 1982 Jun 11;216(4551):1185-92. (PMID: 6281891)
Pain. 2005 Sep;117(1-2):137-44. (PMID: 16055269)
Exp Brain Res. 2009 Dec;199(3-4):203-34. (PMID: 19777221)
Brain Sci. 2020 Jul 20;10(7):. (PMID: 32698378)
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13. (PMID: 9689128)
Lancet Infect Dis. 2022 Apr;22(4):e102-e107. (PMID: 34951953)
Adv Exp Med Biol. 2021;1318:109-118. (PMID: 33973175)
Biol Psychiatry. 2008 Sep 15;64(6):527-32. (PMID: 18571629)
Front Nutr. 2021 Dec 10;8:784429. (PMID: 34957187)
Pain. 2019 Jan;160(1):77-82. (PMID: 30586074)
J Med Virol. 2022 May;94(5):1846-1865. (PMID: 35076118)
Pain. 2022 Jul 1;163(7):1220-1231. (PMID: 34561390)
Pathophysiology. 2022 Jan 19;29(1):24-29. (PMID: 35366287)
Pharmacogenomics. 2013 Nov;14(15):1915-25. (PMID: 24236490)
Adv Rheumatol. 2021 May 12;61(1):24. (PMID: 33980293)
PLoS Genet. 2008 Jul 25;4(7):e1000086. (PMID: 18654615)
J Pain. 2005 Mar;6(3):149-58. (PMID: 15772908)
Pharmacogenet Genomics. 2012 Sep;22(9):673-91. (PMID: 22722321)
Drugs Today (Barc). 2011 Jun;47(6):457-67. (PMID: 21695287)
J Pain. 2012 Nov;13(11):1068-74. (PMID: 23025981)
Cureus. 2020 Aug 28;12(8):e10103. (PMID: 32879833)
J Pain. 2011 Nov;12(11 Suppl):T92-101. (PMID: 22074755)
Contributed Indexing:: Keywords: COVID-19; pain; post-COVID; risk; single nucleotide polymorphism
Entry Date(s):: Date Created: 20220727 Date Completed: 20220728 Latest Revision: 20230308
Update Code:: 20240104
PubMed Central ID:: PMC9394327
DOI:: 10.3390/genes13081336
PMID:: 35893072
: Czasopismo naukowe

Full Text Finder

Objective: To investigate the association of different, selected pain polymorphisms with the presence of de novo long-COVID pain symptoms and to analyze the association between these polymorphisms with clinical, sensory-related, cognitive and psychological variables in COVID-19 survivors. Methods: Two hundred and ninety-three (n = 293, 49.5% female, mean age: 55.6 ± 12.9 years) previously hospitalized COVID-19 survivors participated. Three genotypes of the following single nucleotide polymorphisms (SNPs) were obtained from non-stimulated saliva: OPRM1 (rs1799971), COMT (rs4680), BDNF (rs6265), and HTR1B (rs6296) by polymerase chain reactions in all participants. Further, clinical (intensity/duration of pain), sensory-related (sensitization-associated symptoms, neuropathic pain features), psychological (anxiety or depressive levels, sleep quality), and cognitive (catastrophizing, kinesiophobia) variables were collected in those COVID-19 survivors suffering from post-COVID pain. Analyses were carried out to associate clinical features with genotype. Results: Participants were assessed 17.8 ± 5.2 months after hospitalization. One hundred and seventeen (39.9%) experienced post-COVID pain (particularly of musculoskeletal origin). The distributions of the genotype variants of any SNP were not significantly different between COVID-19 survivors with and without long-term post-COVID pain (all, p > 0.178). No differences in sensitization-associated symptoms, neuropathic pain features, catastrophizing, kinesiophobia levels, anxiety and depressive levels or sleep quality according to the genotype variant in any SNPs were found. No effect of gender was identified. Conclusion: The four SNPs generally associated with pain did not appear to predispose to the development of de novo long-COVID pain symptoms in previously hospitalized COVID-19 survivors. The SNPs were not involved in the phenotypic features of post-COVID pain either.
Competing Interests: The authors declare no conflict of interest.

Informacja